Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer

This study aims to evaluate the efficacy and safety of hypofractionated intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy in patients with cervical cancer. Conventional treatment usually requires 7-8 weeks, which increases the risk of toxicities and treatment delays. This trial seeks to shorten the overall treatment time while maintaining non-inferior tumor response and survival outcomes compared to standard therapy. The primary endpoint is tumor volume reduction rate (TVRR) assessed by pelvic MRI at 1 month after treatment. Secondary endpoints include 3-year l

Trial Details

NCT ID
NCT07439497
Phase
PHASE2
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Definitive hypofractionated intensity-modulated radiation theraphy
  • concurrent chemotherapy
Locations (sample)
  • Seoul, Gangnam-gu, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma)
  • FIGO stage IIB-IVA (2018)
  • Measurable primary tumor on pelvic MRI within 30 days prior to treatment initiation
  • Age ≥ 20 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →